公开(公告)号：US20250066421A1

公开(公告)日：2025-02-27

申请号：US18906616

申请日：2024-10-04

Applicant: BicycleTx Limited

Inventor： Paul Beswick ,  Liuhong Chen ,  Gemma Elizabeth Mudd ,  Peter Park ,  Katerine Van Rietschoten ,  Michael Rigby ,  Stephen Blakemore ,  Tara Gelb ,  Nicholas Keen

IPC: C07K7/08 ,  A61K31/40 ,  A61K31/5375 ,  A61K38/00 ,  A61K38/10 ,  A61K47/55 ,  A61K47/64 ,  A61K47/65 ,  A61P35/00

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

公开(公告)号：US20250051316A1

公开(公告)日：2025-02-13

申请号：US18706735

申请日：2022-11-04

Applicant: SHANGHAI HANSOH BIOMEDICAL CO., LTD. ,  JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.

Inventor： Yidong Su ,  Kailong Li ,  Zhiqiang Huang ,  Haining Deng ,  Xiaohan Zhou ,  Wensheng Yu

IPC: C07D413/04 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/553 ,  C07D265/30 ,  C07D267/10

Abstract: Provided are a 2-(aryl-2-yl) morpholine and a deuterated derivative thereof, a preparation method therefor and an application thereof. In particular, involved are the use of a compound shown by general formula (V) in the treatment of central nervous system diseases, a deuterated compound thereof, a preparation method of deuterated compound, a pharmaceutical composition containing the deuterated compound, and the use thereof as a TAAR1 agonist in the treatment of central nervous system diseases.

公开(公告)号：US20250025479A1

公开(公告)日：2025-01-23

申请号：US18581836

申请日：2024-02-20

Applicant: Joel STUDIN

Inventor： Joel STUDIN

IPC: A61K31/58 ,  A61K9/00 ,  A61K9/06 ,  A61K31/167 ,  A61K31/245 ,  A61K31/381 ,  A61K31/435 ,  A61K31/451 ,  A61K31/4706 ,  A61K31/5375 ,  A61K31/575 ,  A61K47/08 ,  A61K47/10 ,  A61K47/34 ,  A61K47/38 ,  A61K47/42 ,  A61P17/02

Abstract: Compositions and methods of treatment involving transpore delivery of an active ingredient are provided.

公开(公告)号：US20250009752A1

公开(公告)日：2025-01-09

申请号：US18891542

申请日：2024-09-20

Applicant: Supernus Pharmaceuticals, Inc.

Inventor： Christopher D. BREDER

IPC: A61K31/5375 ,  A61K31/00

Abstract: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

公开(公告)号：US12180152B2

公开(公告)日：2024-12-31

申请号：US17876138

申请日：2022-07-28

Applicant: Ozchela Inc.

Inventor： Min-Kyung Lee ,  Jin-Kak Lee ,  Won-Seok Han

IPC: C07D241/04 ,  A61K31/235 ,  A61K31/277 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/5375 ,  C07C15/52 ,  C07C63/331 ,  C07C229/68 ,  C07C253/30 ,  C07C255/35 ,  C07C255/37 ,  C07C255/41 ,  C07C255/42 ,  C07D207/08 ,  C07D213/79 ,  C07D213/80 ,  C07D221/00 ,  C07D265/30 ,  C07D295/155 ,  C07D295/192

Abstract: This invention relates to a stilbene derivative and a method of preparing the same, and more particularly to a novel stilbene derivative for inhibiting the function of cyclophilin, which is effective at the prevention of cyclophilin-related diseases or at the treatment of symptoms of such diseases, and to a method of preparing the same.

公开(公告)号：US12178854B2

公开(公告)日：2024-12-31

申请号：US16631762

申请日：2018-07-19

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Yi Zhang ,  Azusa Inoue

IPC: A61K38/44 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/706

Abstract: The invention provides methods for activating a repressed allele within an imprinting control region, thereby treating an imprinting associated disorder.

公开(公告)号：US20240415842A1

公开(公告)日：2024-12-19

申请号：US18820232

申请日：2024-08-29

Applicant: AXSOME THERAPEUTICS, INC.

Inventor： Herriot Tabuteau

IPC: A61K31/5375 ,  A61P25/20

Abstract: Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.

公开(公告)号：US20240400616A1

公开(公告)日：2024-12-05

申请号：US18427414

申请日：2024-01-30

Applicant: BicycleTx Limited

Inventor： Paul BESWICK ,  Liuhong CHEN ,  Gemma MUDD ,  Peter PARK ,  Katerine VAN RIETSCHOTEN ,  Michael RIGBY

IPC: C07K7/08 ,  A61K31/40 ,  A61K31/5375 ,  A61K38/00 ,  A61K38/10 ,  A61K47/55 ,  A61K47/64 ,  A61K47/65 ,  A61P35/00

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.

公开(公告)号：US20240366833A1

公开(公告)日：2024-11-07

申请号：US18142198

申请日：2023-05-02

Applicant: Allure Medical Spa PLLC

Inventor： Charles Mok

IPC: A61L27/20 ,  A61K9/00 ,  A61K31/167 ,  A61K31/245 ,  A61K31/47 ,  A61K31/5375 ,  A61L27/54

Abstract: A composition and a method for generating a dermal filler are illustrated. The composition comprises an injectable filler, wherein the injectable filler further comprises a plurality of hyaluronic acids and a sugar alcohol. The method comprises obtaining an injectable filler, diluting the injectable filler using a sugar alcohol, and transferring the diluted injectable filler to a syringe to reduce a particle size of the injectable filler.

公开(公告)号：US20240360077A1

公开(公告)日：2024-10-31

申请号：US18537093

申请日：2023-12-12

Applicant: Aeromics, Inc.

Inventor： Marc F. Pelletier ,  George William Farr ,  Paul Robert McGuirk ,  Christopher H. Hall ,  Walter F. Boron

IPC: C07C235/64 ,  A61K31/167 ,  A61K31/24 ,  A61K31/5375 ,  A61K31/661 ,  A61K31/6615 ,  C07D295/185 ,  C07F9/12

CPC classification number: C07C235/64 ,  A61K31/167 ,  A61K31/24 ,  A61K31/5375 ,  A61K31/661 ,  A61K31/6615 ,  C07D295/185 ,  C07F9/12

Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases ofwater imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.